Published in J Gastroenterol on May 01, 2006
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med (1996) 9.85
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med (1998) 7.60
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med (1992) 7.40
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol (2002) 6.74
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol (2001) 6.07
Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol (2005) 5.19
Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med (1997) 4.94
Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol (2003) 2.86
Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol (1999) 2.77
Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol (1997) 2.73
Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol (2004) 2.68
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol (2003) 2.31
Fraction size and dose parameters related to the incidence of pericardial effusions. Int J Radiat Oncol Biol Phys (1998) 1.76
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol (2004) 1.64
Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Gastroenterol (2006) 1.23
Systemic treatment for oesophageal cancer. Eur J Cancer (2005) 0.81
Acute and delayed effects of radiotherapy in patients with oesophageal squamous cell carcinoma treated with chemotherapy, surgery and pre- and postoperative radiotherapy. Acta Oncol (1994) 0.76
Chemoradiation: A Superior Alternative for the Primary Management of Esophageal Carcinoma. Semin Radiat Oncol (1994) 0.75
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol (2011) 5.39
Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet (2008) 2.89
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol (2010) 2.73
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol (2015) 2.70
Efficacy of clinical pathway for the management of mucosal gastric carcinoma treated with endoscopic submucosal dissection using an insulated-tip diathermic knife. Intern Med (2004) 1.93
Seronegative alpha-fetoprotein-producing early gastric cancer treated with endoscopic mucosal resection and additional surgery. Intern Med (2004) 1.45
Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans. Cancer Prev Res (Phila) (2009) 1.31
Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol (2008) 1.27
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study. Jpn J Clin Oncol (2004) 1.26
Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol (2009) 1.21
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms. Cancer Sci (2011) 1.17
Predictive factors of lymph node metastasis in patients with undifferentiated early gastric cancers. J Clin Gastroenterol (2006) 1.08
Involvement of integrin-linked kinase in carbon tetrachloride-induced hepatic fibrosis in rats. Hepatology (2006) 1.06
Granular cell tumor occurring in the sigmoid colon treated by endoscopic mucosal resection using a transparent cap (EMR-C). J Gastroenterol (2003) 1.05
Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol (2009) 1.05
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci (2011) 1.03
MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer (2008) 1.03
The pathophysiology of non-steroidal anti-inflammatory drug (NSAID)-induced mucosal injuries in stomach and small intestine. J Clin Biochem Nutr (2011) 1.03
Gastric cancer concomitant with inflammatory fibroid polyp treated with endoscopic mucosal resection using an insulation-tip diathermic knife. Intern Med (2003) 0.98
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells. J Gastroenterol (2011) 0.96
Current status of Kampo (Japanese herbal) medicines in Japanese clinical practice guidelines. Complement Ther Med (2008) 0.96
Prevalence and characteristics of asymptomatic excessive transmural injury after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm (2011) 0.94
Prediction of the effect of capecitabine in gastric cancer by immunohistochemical staining of thymidine phosphorylase and dihydropyrimidine dehydrogenase. Anticancer Drugs (2008) 0.94
Neoplastic transformation and induction of H+,K+ -adenosine triphosphatase by N-methyl-N'-nitro-N-nitrosoguanidine in the gastric epithelial RGM-1 cell line. In Vitro Cell Dev Biol Anim (2007) 0.92
NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci (2013) 0.92
Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction. Jpn J Clin Oncol (2010) 0.91
Extensive liver metastasis of gastric cancer effectively treated by hepatic arterial infusion of 5-fluorouracil/cisplatin. Gastric Cancer (2000) 0.91
Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer. Anticancer Drugs (2006) 0.91
The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells. Oncol Res (2013) 0.90
Hepatocyte-specific deletion of heme oxygenase-1 disrupts redox homeostasis in basal and oxidative environments. Tohoku J Exp Med (2008) 0.90
Cyclophosphamide enhances antitumor efficacy of oncolytic adenovirus expressing uracil phosphoribosyltransferase (UPRT) in immunocompetent Syrian hamsters. Int J Cancer (2013) 0.90
Effect of combined treatment with the epirubicin-incorporating micelles (NC-6300) and 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016) on a human gastric cancer model. Int J Cancer (2013) 0.89
Effectiveness of an endoscopic biopsy procedure using EUS-FNA and EMR-C for diagnosing adenocarcinoma arising from ectopic pancreas: two case reports and a literature review. Intern Med (2014) 0.89
Gastric acid induces mitochondrial superoxide production and lipid peroxidation in gastric epithelial cells. J Gastroenterol (2011) 0.89
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol (2004) 0.89
Multiple synchronous early gastric carcinoma with seven lesions. J Gastroenterol (2003) 0.89
Risk factors for submucosal and lymphovascular invasion in gastric cancer looking indicative for endoscopic submucosal dissection. Gastric Cancer (2013) 0.88
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. J Cancer Res Clin Oncol (2014) 0.88
Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. Jpn J Clin Oncol (2007) 0.86
[A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer]. Gan To Kagaku Ryoho (2008) 0.86
Geranylgeranylacetone protects the human gastric mucosa from diclofenac-induced injury via induction of heat shock protein 70. Digestion (2007) 0.86
Diagnosis of drug-induced liver injury in Japanese patients by criteria of Consensus Meetings in Europe. Hepatol Res (2003) 0.85
Unusual metastasis of hepatocellular carcinoma to the esophagus. Intern Med (2005) 0.85
[Malignant lymphoma with submucosal invasion in the terminal ileum diagnosed with colonoscopy and examined by endoscopic ultrasonography]. Nihon Shokakibyo Gakkai Zasshi (2004) 0.85
Docetaxel and cisplatin in patients with advanced or recurrent gastric cancer: a multicenter phase I/II study. Gastric Cancer (2002) 0.85
Lansoprazole inhibits mitochondrial superoxide production and cellular lipid peroxidation induced by indomethacin in RGM1 cells. J Clin Biochem Nutr (2011) 0.85
NSAIDs and acidic environment induce gastric mucosal cellular mitochondrial dysfunction. Digestion (2012) 0.83
[A case of Cronkhite-Canada syndrome associated with cholangiocellular carcinoma]. Nihon Shokakibyo Gakkai Zasshi (2005) 0.83
Bisphosphonate-induced gastrointestinal mucosal injury is mediated by mitochondrial superoxide production and lipid peroxidation. J Clin Biochem Nutr (2012) 0.83
Cellular membrane fluidity measurement by fluorescence polarization in indomethacin-induced gastric cellular injury in vitro. J Gastroenterol (2007) 0.83
Alcohol is an oxidative stressor for gastric epithelial cells: detection of superoxide in living cells. J Clin Biochem Nutr (2013) 0.82
The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine. Eur J Cancer (2004) 0.81
A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiat Oncol (2013) 0.81
E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers. Clin Cancer Res (2007) 0.81
Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis. World J Gastroenterol (2013) 0.81
Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin. Jpn J Clin Oncol (2007) 0.80
Peroxiredoxin I protects gastric mucosa from oxidative injury induced by H. pylori infection. J Gastroenterol Hepatol (2007) 0.80
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study). Jpn J Clin Oncol (2011) 0.80
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. Cancer Chemother Pharmacol (2015) 0.80
Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status. Med Oncol (2014) 0.79
EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus. Int J Cancer (2011) 0.79
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol (2005) 0.79
A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer. Cancer Chemother Pharmacol (2015) 0.78
[A retrospective analysis of cetuximab or panitumumab monotherapy for KRAS wild-type metastatic colorectal cancer in clinical practice]. Gan To Kagaku Ryoho (2015) 0.78
Incidence and underlying etiologies of bronchial secretion in terminally ill cancer patients: a multicenter, prospective, observational study. J Pain Symptom Manage (2004) 0.78
Predicting skin toxicity according to EGFR polymorphisms in patients with colorectal cancer receiving antibody against EGFR. Anticancer Res (2013) 0.78
Artificial hydration therapy, laboratory findings, and fluid balance in terminally ill patients with abdominal malignancies. J Pain Symptom Manage (2006) 0.78
[A case of malignant peritoneal mesothelioma with the epithelioid histological type, successfully treated with pemetrexed plus cisplatin]. Gan To Kagaku Ryoho (2014) 0.78
Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma. Int J Cancer (2008) 0.78
A phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer. Cancer Chemother Pharmacol (2005) 0.78
A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer. Gastric Cancer (2013) 0.77
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Invest New Drugs (2013) 0.77
Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study. Int J Clin Oncol (2014) 0.77
Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer. BMC Cancer (2013) 0.77
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial. Jpn J Clin Oncol (2008) 0.76
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. Cancer Chemother Pharmacol (2003) 0.76
Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis. Intern Med (2016) 0.76
Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer. Onkologie (2013) 0.75
Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion. Gastrointest Cancer Res (2007) 0.75
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). Jpn J Clin Oncol (2003) 0.75
A Rare Case of Colonic Leiomyosarcoma in Association with Ulcerative Colitis. Intern Med (2016) 0.75
Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer? Gastric Cancer (2012) 0.75
How should oncologists face complementary and alternative medicine? Jpn J Clin Oncol (2008) 0.75
Timing of significant adverse events is essential information during early development of new drugs. Int J Clin Oncol (2006) 0.75
[Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer]. Gan To Kagaku Ryoho (2004) 0.75
[Clinical study of irinotecan therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer]. Gan To Kagaku Ryoho (2004) 0.75
Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Drug Metab Pharmacokinet (2013) 0.75
High orotate phosphoribosyltransferase gene expression predicts complete response to chemoradiotherapy in patients with squamous cell carcinoma of the esophagus. Oncology (2009) 0.75
[Standard chemotherapy for colonic neoplasms]. Nihon Naika Gakkai Zasshi (2007) 0.75
Collagenous sprue diagnosed by double balloon endoscopy. Dig Endosc (2012) 0.75
[Clinical study of TS-1 therapy for inoperable and recurrent gastric cancer]. Gan To Kagaku Ryoho (2003) 0.75
[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody]. Nihon Rinsho (2011) 0.75
Tizanidine-induced hypotension in patients with liver cirrhosis. Eur J Clin Pharmacol (2008) 0.75
[A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient]. Gan To Kagaku Ryoho (2004) 0.75
Extragonadal retroperitoneal embryonal carcinoma successfully treated with chemotherapy. Intern Med (2003) 0.75
[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]. Gan To Kagaku Ryoho (2007) 0.75